12:23 PM EDT, 06/24/2024 (MT Newswires) -- Argenx (ARGX) shares rose past 12% in recent Monday trading after the US Food and Drug Administration approved Vyvgart Hytrulo to treat adults with chronic inflammatory demyelinating polyneuropathy.

The approval triggered a slew of price target increases from analysts, including from BofA Securities to $607 from $535, Stifel to $500 from $485, Piper Sandler to $535 from $522 and Wells Fargo to $542 from $478.

Trading volume stood at about 388,800 shares against a daily average of nearly 254,900 shares.

Price: 444.05, Change: +49.58, Percent Change: +12.57